Reading the tape
NASDAQ: VRTX
Vertex Pharmaceuticals Incorporated
Healthcare · Biotechnology
Market Cap
$109.09B
52w High
$507.92
52w Low
$362.50
P/E
25.04
Volume
953.02K
Outstanding Shares
253.81M
Price vs Fundamentals
Why The Stock Is Moving
Mixed / unclearLow confidence
1Y Price: 0.05%Revenue (TTM): 10.41%FCF (TTM): 394.94%P/FCF: 38th pct
What changed
The stock rose 0.05% over the last year. Revenue grew 10.41% over the trailing twelve months. Operating margin moved from -6.69% to 38.97%. Free cash flow grew 394.94% over the trailing twelve months.
What the market seems to be pricing
The stock has moved higher against modestly improving underlying metrics. The operating data does not yet tell a clear story — the move may reflect sentiment, sector rotation, or macro factors rather than company-specific earnings power.
What would invalidate this read
Operating margin currently stands at 38.97%. A decisive move in revenue — currently up 10.41% — would be the clearest signal to resolve the ambiguity.
Company profile
Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis.
CEOReshma Kewalramani
SectorHealthcare
IndustryBiotechnology
Employees6,100
IPO dateJul 24, 1991
Valuation
Forward P/E—
EV/EBITDA23.09
Enterprise value$114.72B
Stock splits
Aug 24, 2000↑ Forward
Every 1 shares became 2
Profitability & growth
Revenue growth7.82%
Gross margin86.28%▼1.25%vs FY2024
Operating margin38.97%▲1965.58%vs FY2024
ROE21.18%▲748.87%vs FY2024
Analyst consensus
RatingBuy
Target price$552.80▲28.61%
48
Buy
8
Hold
0
Sell
Analyst ratings tend to be lagging indicators. Use as one signal among many.
Earnings
Full quarter-by-quarter history of actuals vs estimates. Switch into compare mode to inspect one metric year-over-year.
Next report
Aug 3, 2026
Q3 FY26 · EPS est $4.72 · Revenue est $3.22B
View